Bodyweight gain associated with atypical antipsychotics: Epidemiology and therapeutic implications

CNS Drugs

Volumn 15, Issue 7, 2001, Pages 537-551

  Russell, J M ^a   Mackell, J A ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; ZOTEPINE;

AGE; BODY MASS; BODY WEIGHT; COGNITIVE DEFECT; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTRIGLYCERIDEMIA; NEGATIVE SYNDROME; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RELAPSE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SOCIAL ASPECT; WEIGHT GAIN;

EID: 0034910756     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115070-00004     Document Type: Review

References (104)

1. Weight gain associated with atypical antipsychotics
2. Side effect profiles of new antipsychotic agents
3. The relationship of pharmacology to side effects
4. From chlorpromazine to olanzapine: A brief history of antipsychotics
5. Recent advances in the pharmacotherapy of schizophrenia
6. Clozapine: A novel antipsychotic agent
7. Measuring outcome in schizophrenia: Differences among the atypical antipsychotics
8. Tolerability and therapeutic effect of clozapine
9. Weight gain associated with psychotropic drugs
10. Clozapine-induced weight gain: Prevalence and clinical relevance
11. Clozapine and weight gain
12. Diet and gender moderate clozapine-related weight gain
13. Weight gain induced by clozapine
14. Weight gain with risperidone
15. Weight changes during clozapine treatment
16. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
17. Olanzapine: Weight gain and therapeutic efficacy
18. Antipsychotic-induced weight gain: A comprehensive research synthesis
19. Weight gain associated with use of psychotropic medications
20. Effects of psychotropic drugs on weight
21. Atypical antipsychotics and weight gain - A systematic review
22. Bodyweight change as an adverse effect of drug treatment
23. Weight gain among schizophrenic patients treated with clozapine
24. Weight gain associated with clozapine
25. Quetiapine in patients with schizophrenia: A high and low-dose double-blind comparison with placebo
26. Weight gain and antipsychotic medications
27. Novel antipsychotics: Comparison of weight gain liabilities
28. Safety of olanzapine
29. Olanzapine increases weight and serum triglyceride levels
30. Complications of obesity
31. Overweight and cancer
32. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men
33. Compliance with antipsychotic drug treatment: Influence of side effects
34. Weight gain as a risk factor for clinical diabetes mellitus in women
35. Obesity treatment: Examining the premises
36. Cigarette smoking, weight gain, and coronary mortality: Results from the Chicago Western Electric study
37. A prospective study of body mass index, weight change, and risk of stroke in women
38. Antipsychotics linked to weight gain diabetes
39. Relative weight gain among antipsychotics
40. Physical and psychological consequences of weight gain
41. Serum triglyceride levels in patients treated with clozapine
42. Diabetes and schizophrenia - A preliminary study
43. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
44. Letters to the editor
45. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapinetreated patients
46. Weight gain as a predictor of long-term clozapine efficacy
47. Differential effects of clozapine on weight: A controlled study
48. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
49. Clozapine and body mass change
50. Bodyweight and leptin plasma levels during treatment with antipsychotic drugs
51. Weight gain: Side effect of atypical neuroleptics?
52. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study
53. Risperidone versus phenelzine in the treatment of chronic schizophrenic patients with acute exacerbations
54. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, doubleblind, parallel-group study versus haloperidol
55. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
56. Safety of olanzapine
57. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: Results of an international collaborative trial
58. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
59. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
60. Quetiapine ('Seroquel'): An effective and well tolerated atypical antipsychotic
61. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
62. Quetiapine: A review of its use in schizophrenia
63. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
64. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
65. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
66. Ziprasidone: A new highly atypical antipsychotic
67. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
68. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
69. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group, double-blind trial
70. Clozapine-induced weight gain
71. Lithium and body weight-gain
72. Drug-induced weight gain
73. Measurement of appetite disturbances in psychiatric disorders
74. Weight gain with clozapine treatment
75. Risperidone in the treatment of schizophrenia
76. Weight gain associated with antipsychotic drugs
77. Dosing the antipsychotic medication olanzapine
78. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control
79. Zotepine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
80. Safety profile of amisulpride in short and long-term use
81. Neuropharmacology of obesity: My receptors made me eat it
82. Radioreceptor binding profile of the atypical antipsychotic olanzapine
83. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
84. Focus on olanzapine
85. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients
86. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia
87. Weight gain associated with neuroleptic medication: A review
88. Clozapine associated with diabetes mellitus
89. Novel antipsychotics and new onset diabetes
90. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
91. Hyperglycemia and olanzapine
92. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
93. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine
94. Clozapine-associated elevation in serum triglyceride levels
95. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 Year follow up of participants in the study of men born in 1913
96. Weight change and risk of heart attack in middle-aged British men
97. Psychosocial factors and quality of life in obesity
98. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
99. Review of recent clinical studies with olanzapine
100. Olanzapine: A pharmacoeconomic review of its use in schizophrenia
101. Nonpharmacologic and pharmacologic management of weight gain
102. Amantadine in the treatment of neuroleptic-induced obesity in rats: Behavioral, endocrine and neurochemical correlates
103. Body weight gain induced by antipsychotic drugs: Mechanisms and management